Keloids - Pipeline Insight, 2021

DelveInsights, Keloids - Pipeline Insight, 2021, report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Keloids pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Keloids Understanding
Keloids: Overview
Keloids are raised overgrowths of scar tissue that occur at the site of a skin injury. They occur where trauma, surgery, blisters, vaccinations, acne or body piercing have injured the skin. Keloid scars tend to be larger than the original wound itself. They are shiny, smooth and rounded skin elevations that may be pink, purple, or brown. Most types of skin injury can contribute to keloid scarring. Keloids should not be confused with hypertrophic scars, which are raised scars that do not grow beyond the boundaries of the original wound and may reduce over time. A dermatologist diagnoses a keloid on the basis of its appearance and a history of tissue injury, such as surgery, acne or body piercing. Available treatments include: Removal with conventional surgery, Dressings, Corticosteroid injections, Compression, Cryosurgery, Radiation therapy, Laser therapy, and Fluorouracil injections.

"Keloids - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloids pipeline landscape is provided which includes the disease overview and Keloids treatment guidelines. The assessment part of the report embraces, in depth Keloids commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloids collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Keloids R&D. The therapies under development are focused on novel approaches to treat/improve Keloids.

Keloids Emerging Drugs Chapters
This segment of the Keloids report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Keloids Emerging Drugs
STP705: Sirnaomics
STP705 is a siRNA therapeutic comprising of two oligonucleotides with directly knock down of both TGF-1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA, including treatments of cholangiocarcinoma, nonmelanoma skin cancer, and hypertrophic scar. The drug is in Phase II clinical studies for the treatment of Keloids.

LEM-S401: Lemonex
LEM-S401 is a DegradaBALL-siRNA being developed to treat skin fibrosis. LEM-S401 down-regulates the expression of CTGF and downstream genes such as collagen types I and III, which are over-expressed in fibrotic tissues in vitro and in vivo. The drug is in preclinical studies for the treatment of Keloids.
Further product details are provided in the report..

Keloids: Therapeutic Assessment
This segment of the report provides insights about the different Keloids drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Keloids
There are approx. 4+ key companies which are developing the therapies for Keloids. The companies which have their Keloids drug candidates in the most advanced stage, i.e. Phase II include, Sirnaomics.

Phases
DelveInsights report covers around 4+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Keloids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Keloids: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Keloids therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloids drugs.

Keloids Report Insights
Keloids Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Keloids Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Keloids drugs?
How many Keloids drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Keloids?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Keloids therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Keloids and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Yuhan
Lemonex
BirchBioMed
Sirnaomics

Key Products
YH-siRNA1
LEM-S401
Kynurenic acid
STP705

Introduction
Executive Summary
Keloids: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Keloids DelveInsights Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
STP705: Sirnaomics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
LEM-S401: Lemonex
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Keloids Key Companies
Keloids Key Products
Keloids- Unmet Needs
Keloids- Market Drivers and Barriers
Keloids- Future Perspectives and Conclusion
Keloids Analyst Views
Appendix

List Of Tables

Table 1 Total Products for Keloids
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Keloids
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available